Testosterone undecanoate

Last updated

Testosterone undecanoate
Testosterone undecanoate.svg
Testosterone undecanoate molecule ball.png
Clinical data
Pronunciation /tɛˈstɒstəroʊnənˈdɛkənoʊeɪt/ teh-STOS-tə-rohn ən-DEK-ə-noh-ayt
Trade names Oral: Kyzatrex, Andriol, Jatenzo, Testoheal, others
IM: Aveed, Nebido, others
Other namesTU; Testosterone undecylate; Testosterone 17β-undecanoate; ORG-538; CLR-610
AHFS/Drugs.com Monograph
MedlinePlus a614041
License data
Pregnancy
category
Dependence
liability 		Moderate [2]
Addiction
liability 		Moderate [2]
Routes of
administration 		By mouth, intramuscular injection
Drug class Androgen; Anabolic steroid; Androgen ester
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: 3–7%[ medical citation needed ]
Intramuscular: high
Protein binding High (testosterone)
Metabolism Liver
Metabolites Testosterone, undecanoic acid, metabolites of testosterone
Elimination half-life IM Tooltip Intramuscular injection (in tea seed oil): 20.9 days [7] [8]
IM (in castor oil): 33.9 days [7] [8]
Excretion ~90% Urine, 6% feces
Identifiers
  • [(8R,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.025.193 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C30H48O3
Molar mass 456.711 g·mol−1
3D model (JSmol)
  • CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
  • InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1 X mark.svgN
  • Key:UDSFVOAUHKGBEK-CNQKSJKFSA-N X mark.svgN
   (verify)

Testosterone undecanoate, sold under the brand name Nebido among others, is an androgen and anabolic steroid (AAS) medication that is used mainly in the treatment of low testosterone levels in men, [9] [7] [10] [11] [12] [13] [14] It is taken by mouth or given by injection into muscle. [11] [15]

Contents

Side effects of testosterone undecanoate include symptoms of masculinization like acne, increased hair growth, voice changes, hypertension, elevated liver enzymes, hypertriglyceridemia, and increased sexual desire. [11] The drug is a prodrug of testosterone, the biological ligand of the androgen receptor (AR) and hence is an androgen and anabolic steroid. [16] [11] It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization and suitable for androgen replacement therapy. [11] Testosterone undecanoate is a testosterone ester and a prodrug of testosterone in the body. [10] [9] [7] Because of this, it is considered to be a natural and bioidentical form of testosterone. [17]

Testosterone undecanoate was introduced in China for use by injection and in the European Union for use by mouth in the 1970s. [18] [19] It became available for use by injection in the European Union in the early to mid 2000s and in the United States in 2014. [20] [21] Formulations for use by mouth are approved in the United States. [4] [5] [22] Along with testosterone enanthate, testosterone cypionate, and testosterone propionate, testosterone undecanoate is one of the most widely used testosterone esters. [16] [7] [11] However, it has advantages over other testosterone esters in that it can be taken by mouth and in that it has a far longer duration when given by injection. [23] [9] [7] [8] [11] In addition to its medical use, testosterone undecanoate is used to improve physique and performance. [11] The drug is a controlled substance in many countries. [11]

Oral administration of testosterone undecanoate is an effective method to achieve therapeutic physiological levels of serum testosterone in patients with hypogonadism. In addition, oral therapy has been found to have a positive impact in these patients on quality of life factors such as sexual function, mood, and mental status, as documented in various studies. [24]

Medical uses

Testosterone undecanoate is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [4] [5] [6]

Side effects

Side effects of testosterone undecanoate include virilization among others. [11]

Anaphylaxis

The Reandron 1000 formulation (Aveed in the United States) contains 1,000 mg of testosterone undecanoate suspended in 4 ml castor oil with benzyl benzoate for solubilization and as a preservative, and is administered by intramuscular injection. As an excipient in Reandron 1000, benzyl benzoate has been reported as a cause of anaphylaxis (a serious life-threatening allergic reaction) in a case in Australia. [25] Bayer includes this report in information for health professionals and recommends that physicians "should be aware of the potential for serious allergic reactions" to preparations of this type. [26] In Australia, reports to the Adverse Drug Reactions Advisory Committee (ADRAC), which evaluates reports of adverse drug reactions for the Therapeutic Goods Administration (TGA), show several reports of allergic reactions since the anaphylaxis case from 2011.[ medical citation needed ]

Pharmacology

Pharmacodynamics

Androgenic vs. anabolic activity ratio
of androgens/anabolic steroids
MedicationRatioa
Testosterone ~1:1
Androstanolone (DHT) ~1:1
Methyltestosterone ~1:1
Methandriol ~1:1
Fluoxymesterone 1:1–1:15
Metandienone 1:1–1:8
Drostanolone 1:3–1:4
Metenolone 1:2–1:30
Oxymetholone 1:2–1:9
Oxandrolone 1:3–1:13
Stanozolol 1:1–1:30
Nandrolone 1:3–1:16
Ethylestrenol 1:2–1:19
Norethandrolone 1:1–1:20
Notes: In rodents. Footnotes:a = Ratio of androgenic to anabolic activity. Sources: See template.

Testosterone undecanoate is a prodrug of testosterone and is an androgen and anabolic–androgenic steroid (AAS). That is, it is an agonist of the androgen receptor (AR).

Pharmacokinetics

Testosterone undecanoate has a very long elimination half-life and mean residence time when given as a depot intramuscular injection. [27] [7] [8] Its elimination half-life is 20.9 days and its mean residence time is 34.9 days in tea seed oil, while its elimination half-life is 33.9 days and its mean residence time is 36.0 days in castor oil. [7] [8] These values are substantially longer than those of testosterone enanthate (which, in castor oil, has values of 4.5 days and 8.5 days, respectively). [27]

Testosterone undecaondate has very low bioavailability when taken orally, only about 3-7% in men and 4-10% in women. [28] [29] [30] This bioavailability is increased with food, especially foods containing fat, thus it is typically recommended to be taken with a meal. [31] [32] [33] [34] It is absorbed through the lymphatic system (90-100%) and peak serum levels are reached after about 3-5 hours. [29] [35] [36] From there, plasma levels decline, typically reaching pre-dose levels after 6-12 hours. The elimination half-life via the oral route has been stated to be 1.6 hours, with a mean residence time of 3.7 hours. [7] However, there is a large amount of individual variability in its duration of action. [37] For this reason it is often dosed twice or even three times a day. [37] [35]

Testosterone undecanoate is metabolized partially in the intestinal wall into 5-alpha-dihydrotestosterone undecanoate (DHTU). [38] In the blood, non-specific esterases metabolize testosterone undecanoate into testosterone and DHTU into dihydrotestosterone (DHT). [38] Thus, testosterone undecanoate increases plasma levels of both testerone and DHT. The fact the conversion happens in the blood complicates the accurate measurement of blood levels of testosterone induced by the drug, as the conversion continues to occur while blood samples are being prepared for assay. Ideally, enzyme inhibitors should be used to properly assay the blood testosterone levels induced by testosterone undecanoate. [38]

Chemistry

Testosterone undecanoate, or testosterone 17β-undecanoate, is a synthetic androstane steroid and a derivative of testosterone. [39] [40] It is an androgen ester; specifically, it is the C17β undecylate (undecanoate) ester of testosterone. [39] [40] A related testosterone ester with a similarly very long duration is testosterone buciclate. [9] [10]

The first commercialized preparation of oral testosterone undecanoate had it dissolved in oleic acid. [37] This formulation had to be refrigerated in the pharmacy for reasons of stability and would only last about three months at room temperature. [37] A newer more stable pharmaceutical formulation with castor oil and propylene glycol laurate has since been developed. [37] This new formulation can be stored at room temperature for three years. [37] A novel self-emulsifying formulation of oral testosterone undecanoate in 300-mg capsules for use once per day has been under development.< [41]

History

In the late 1970s, testosterone undecanoate was introduced for oral use in Europe, [18] although intramuscular testosterone undecanoate had already been in use in China for several years. [19] Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later, in the early to mid 2000s and 2014, respectively. [20] [21] Testosterone undecanoate was approved in the United States only in 2014 after three previous rejections due to safety concerns. [42]

Society and culture

Generic names

Testosterone undecanoate is the generic name of the drug and its USAN Tooltip United States Adopted Name and BAN Tooltip British Approved Name. [39] [40] [43] [44] It is also referred to as testosterone undecylate. [39] [40] [43] [44]

Brand names

Testosterone undecanoate is or has been marketed under a variety of brand names, including Andriol, Androxon, Aveed, Cernos Depot, Jatenzo, Kyzatrex, [6] Nebido, Nebido-R, Panteston, Reandron 1000, Restandol, Sustanon 250, Undecanoate 250, and Undestor. [39] [40] [43] [45] [44]

Availability

Oral testosterone undecanoate is available in Europe, Mexico, Asia, and the United States. [46] [47]

Intramuscular testosterone undecanoate has been approved worldwide, [46] [11] including the European Union, Russia, and the United States. [11] [46] [48] Intramuscular testosterone undecanoate is marketed as Nebido in Europe and as Aveed in the United States while oral testosterone undecanoate is marketed as Andriol. [11] [46] [48]

Testosterone undecanoate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act. [49] [50]

In March 2019, the US Food and Drug Administration approved testosterone undecanoate (Jatenzo), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. [22] The FDA granted the approval of Jatenzo to Clarus Therapeutics. [22] [51]

In March 2022, testosterone undecanoate (Tlando) was approved for medical use in the United States. [5]

In July 2022, Kyzatrex, an oral testosterone undecanoate capsule, was approved for medical use in the United States. [6] [52] The FDA granted the approval of Kyzatrex to Marius Pharmaceuticals. [52] [53]

Research

Non-alcoholic steatohepatitis

In 2013, a phase II clinical trial testing intramuscular testosterone undecanoate for the treatment of non-alcoholic steatohepatitis (NASH) was initiated in the United Kingdom. [54] In the United States in 2018, Lipocine Inc. began investigating the potential of using an oral testosterone undecanoate formulation, known as LPCN-1144, in patients with NASH. [55]

Osteoporosis

In 2013, a study aimed to evaluate the efficacy of testosterone undecanoate therapy on bone mineral density (BMD) and biochemical markers of bone turnover in elderly males with osteoporosis and low serum testosterone levels.

They study found that administering low-dose testosterone undecanoate (TU) at a rate of 20 mg per day to elderly men with low serum testosterone and osteoporosis effectively increases bone mineral density in the lumbar spine and femoral neck, and improves bone turnover, similar to the standard-dose TU (40 mg, per day) treatment. The treatment did not exhibit any adverse side effects on the prostate gland, including prostate-specific antigen. Therefore, low-dose TU appears to be a safe and cost-effective protocol for treating elderly male osteoporosis. [56] However, further clinical trials with larger sample sizes, multiple centers, and long-term follow-ups are required to determine the efficacy and safety of low-dose testosterone undecanoate treatment in elderly male osteoporosis with low serum testosterone.

Health implications

Risks associated with treatment of late-onset hypogonadism

There is a potential concern in the medical community that the administration of testosterone therapy for the treatment of late-onset hypogonadism may escalate the risks associated with benign prostatic hyperplasia, prostate cancer and heart diseases. [57]

Body composition

In 2020, a study that evaluated the effects of testosterone therapy in men with testosterone deficiency and varying degrees of weight (normal weight, overweight, and obesity) on anthropometric and metabolic parameters found that long-term testosterone undecanoate therapy in hypogonadal men, regardless of their weight at the start of the study, led to improvements in several body composition parameters, including body weight, waist circumference, and body mass index. Additionally, testosterone undecanoate therapy was found to lower fasting blood glucose and HbA1c levels and improve lipid profiles in this population. [58]

Bone density

There have been several studies that evaluate the effect of testosterone therapy on bone density or bone mineral density (BMD). One study concluded that long-term testosterone replacement therapy (TRT) in middle-aged men with late-onset hypogonadism (LOH) and metabolic syndrome (MS) led to a significant increase in both vertebral and femoral bone mineral density (BMD) after 36 months of treatment, as measured by dual-energy x-ray absorptiometry. The TRT treatment was shown to induce a 5% per year increase in BMD without changes in body mass index (BMI). The study suggests that long-term TRT could be beneficial for improving bone health in middle-aged men with LOH and MS, even in the absence of osteoporosis. [59]

Related Research Articles

<span class="mw-page-title-main">Methyltestosterone</span> Chemical compound

Methyltestosterone, sold under the brand names Android, Metandren, and Testred among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, at low doses as a component of menopausal hormone therapy for menopausal symptoms like hot flashes, osteoporosis, and low sexual desire in women, and to treat breast cancer in women. It is taken by mouth or held in the cheek or under the tongue.

<span class="mw-page-title-main">Nandrolone</span> Androgenic Anabolic steroid

Nandrolone, also known as 19-nortestosterone, is an endogenous androgen which exists in the male body at a ratio of 1:50 compared to testosterone. It is also an anabolic steroid (AAS) which is medically used in the form of esters such as nandrolone decanoate and nandrolone phenylpropionate. Nandrolone esters are used in the treatment of anemias, cachexia, osteoporosis, breast cancer, and for other indications. They are now used by oral administration or instead are given by injection into muscle or fat.

<span class="mw-page-title-main">Stanozolol</span> Discontinued steroid for heart treatment

Stanozolol, sold under many brand names, is a synthetic androgen and anabolic steroid (AAS) medication derived from dihydrotestosterone (DHT). It is used to treat hereditary angioedema. It was developed by American pharmaceutical company Winthrop Laboratories in 1962, and has been approved by the U.S. Food and Drug Administration for human use, though it is no longer marketed in the USA. It is also used in veterinary medicine. Stanozolol has mostly been discontinued, and remains available in only a few countries. It is given by mouth in humans or by injection into muscle in animals.

<span class="mw-page-title-main">Nandrolone decanoate</span> Anabolic steroid

Nandrolone decanoate, sold under the brand names Rolon and Deca-Durabolin, among others, is an androgen and anabolic steroid (AAS) medication which is used primarily in the treatment of anemias and wasting syndromes, as well as osteoporosis in menopausal women. It is given by injection into muscle or fat once every one to four weeks.

<span class="mw-page-title-main">Testosterone cypionate</span> Chemical compound

Testosterone cypionate, sold under the brand name Depo-Testosterone among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men, including hormone therapy for transgender men. It is given by injection into muscle or subcutaneously, once every one to four weeks, depending on clinical indication.

<span class="mw-page-title-main">Testosterone enanthate</span> Chemical compound

Testosterone enanthate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is given by injection into muscle or subcutaneously usually once every one to four weeks.

<span class="mw-page-title-main">Testosterone propionate</span> Chemical compound

Testosterone propionate, sold under the brand name Testoviron among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It has also been used to treat breast cancer in women. It is given by injection into muscle usually once every two to three days.

<span class="mw-page-title-main">Mesterolone</span> Chemical compound

Mesterolone, sold under the brand name Proviron among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels. It has also been used to treat male infertility, although this use is controversial. It is taken by mouth.

<span class="mw-page-title-main">Trestolone</span> Chemical compound

Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by injection into muscle.

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy in which androgens, often testosterone, are supplemented or replaced. It typically involves the administration of testosterone through injections, skin creams, patches, gels, pills, or subcutaneous pellets. ART is often prescribed to counter the effects of male hypogonadism.

<span class="mw-page-title-main">Selective androgen receptor modulator</span> Class of pharmaceutical drugs

Selective androgen receptor modulators (SARMs) are a class of drugs that selectively activate the androgen receptor in specific tissues, promoting muscle and bone growth while having less effect on male reproductive tissues like the prostate gland.

Masculinizing hormone therapy, also known as transmasculine hormone therapy or female-to-male hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. It is a common type of transgender hormone therapy, and is predominantly used to treat transgender men and other transmasculine individuals who were assigned female at birth. Some intersex people also receive this form of therapy, either starting in childhood to confirm the assigned sex or later if the assignment proves to be incorrect.

<span class="mw-page-title-main">Anabolic steroid</span> Steroidal androgen that is structurally related and has similar effects to testosterone

Anabolic steroids, also known as anabolic-androgenic steroids (AAS), are a class of drugs that are structurally related to testosterone, the main male sex hormone, and produce effects by binding to the androgen receptor (AR). Anabolic steroids have a number of medical uses, but are also used by athletes to increase muscle size, strength, and performance.

<span class="mw-page-title-main">Testosterone decanoate</span> Chemical compound

Testosterone decanoate is an androgen and anabolic steroid and a testosterone ester. It is a component of Sustanon, along with testosterone propionate, testosterone phenylpropionate, and testosterone isocaproate. The medication has not been marketed as a single-drug preparation. Testosterone decanoate has been investigated as a potential long-acting injectable male contraceptive. It has a longer duration of action than testosterone enanthate, but its duration is not as prolonged as that of testosterone undecanoate.

<span class="mw-page-title-main">Nandrolone phenylpropionate</span> Anabolic steroid

Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women. It is given by injection into muscle once every week. Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly no longer available.

<span class="mw-page-title-main">Testosterone buciclate</span> Chemical compound

Testosterone buciclate is a synthetic, injected anabolic–androgenic steroid (AAS) which was never marketed. It was developed in collaboration by the Contraceptive Development Branch (CDB) of the National Institute of Child Health and Human Development (NICHD) and the World Health Organization (WHO) in the 1970s and early 1980s for use in androgen replacement therapy for male hypogonadism and as a potential male contraceptive. It was first described in 1986. The medication is an androgen ester – specifically, the C17β buciclate (4-butylcyclohexane-1-carboxylate) ester of testosterone – and is a prodrug of testosterone with a very long duration of action when used as a depot via intramuscular injection. Testosterone buciclate is formulated as a microcrystalline aqueous suspension with a defined particle size of at least 75% in the range of 10 to 50 μm.

<span class="mw-page-title-main">Testosterone (medication)</span> Medication and naturally occurring steroid hormone

Testosterone (T) is a medication and naturally occurring steroid hormone. It is used to treat male hypogonadism, gender dysphoria, and certain types of breast cancer. It may also be used to increase athletic ability in the form of doping. It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. Testosterone can be used as a gel or patch that is applied to the skin, injection into a muscle, tablet that is placed in the cheek, or tablet that is taken by mouth.

<span class="mw-page-title-main">Dimethandrolone undecanoate</span> Chemical compound

Dimethandrolone undecanoate (DMAU), also known by its developmental code name CDB-4521, is an experimental androgen/anabolic steroid (AAS) and progestogen medication which is under development as a potential birth control pill for men. It is taken by mouth, but can also be given by injection into muscle.

<span class="mw-page-title-main">Androstanolone</span> Androgenic and anabolic steroid medication

Androstanolone, or stanolone, also known as dihydrotestosterone (DHT) and sold under the brand name Andractim among others, is an androgen and anabolic steroid (AAS) medication and hormone which is used mainly in the treatment of low testosterone levels in men. It is also used to treat breast development and small penis in males. Compared to testosterone, androstanolone (DHT) is less likely to aromatize into estrogen, and therefore it shows less pronounced estrogenic side effects, such as gynecomastia and water retention. On the other hand, androstanolone (DHT) show more significant androgenic side effects, such as acne, hair loss and prostate enlargement.

<span class="mw-page-title-main">Pharmacokinetics of testosterone</span>

The pharmacology of testosterone, an androgen and anabolic steroid (AAS) medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.

References

  1. ↑ "Testosterone Use During Pregnancy". Drugs.com. 20 August 2019. Archived from the original on 1 February 2014. Retrieved 18 March 2020.
  2. 1 2 "Anabolic steroid misuse". nhs.uk. 4 November 2022. Retrieved 12 July 2024.
  3. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  4. 1 2 3 "Jatenzo- testosterone undecanoate capsule, liquid filled". DailyMed. 11 January 2021. Archived from the original on 5 January 2022. Retrieved 27 May 2022.
  5. 1 2 3 4 "Tlando- testosterone undecanoate capsule, liquid filled". DailyMed. 28 March 2022. Archived from the original on 3 July 2022. Retrieved 27 May 2022.
  6. 1 2 3 4 "Kyzatrex- testosterone undecanoate capsule, liquid filled". DailyMed. 18 October 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
  7. 1 2 3 4 5 6 7 8 9 Nieschlag E, Behre HM, Nieschlag S (13 January 2010). Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. pp. 441–446. ISBN   978-3-540-78355-8.
  8. 1 2 3 4 5 Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E (May 1999). "Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies". European Journal of Endocrinology. 140 (5): 414–419. CiteSeerX   10.1.1.503.1752 . doi:10.1530/eje.0.1400414. PMID   10229906. S2CID   22597244.
  9. 1 2 3 4 Nieschlag E, Behre HM, Nieschlag S (26 July 2012). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 313–315, 321–322. ISBN   978-1-107-01290-5. Archived from the original on 7 April 2022. Retrieved 3 January 2018.
  10. 1 2 3 Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1185–. ISBN   978-0-7817-1750-2. Archived from the original on 17 May 2020. Retrieved 3 January 2018.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 Llewellyn W (2011). Anabolics. Molecular Nutrition LLC. pp. 180–182, 331–334. ISBN   978-0-9828280-1-4. Archived from the original on 3 July 2022. Retrieved 3 January 2018.
  12. ↑ Irwig MS (April 2017). "Testosterone therapy for transgender men". The Lancet. Diabetes & Endocrinology. 5 (4): 301–311. doi:10.1016/S2213-8587(16)00036-X. PMID   27084565.
  13. ↑ Jacobeit JW, Gooren LJ, Schulte HM (September 2007). "Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals". The Journal of Sexual Medicine. 4 (5): 1479–1484. doi:10.1111/j.1743-6109.2007.00556.x. PMID   17635694.
  14. ↑ Jacobeit JW, Gooren LJ, Schulte HM (November 2009). "Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals". European Journal of Endocrinology. 161 (5): 795–798. doi: 10.1530/EJE-09-0412 . PMID   19749027.
  15. ↑ Bertelloni S, Hiort O (28 September 2010). New Concepts for Human Disorders of Sexual Development. S. Karger AG. pp. 256–. ISBN   978-3-8055-9569-8. Archived from the original on 8 November 2020. Retrieved 3 November 2016.
  16. 1 2 Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC   2439524 . PMID   18500378.
  17. ↑ Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV (April 2016). "Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement". The Journal of Clinical Endocrinology and Metabolism. 101 (4): 1318–1343. doi: 10.1210/jc.2016-1271 . PMID   27032319.
  18. 1 2 Hoberman J (21 February 2005). Testosterone Dreams: Rejuvenation, Aphrodisia, Doping . University of California Press. pp.  134–. ISBN   978-0-520-93978-3.
  19. 1 2 Mundy AR, Fitzpatrick J, Neal DE, George NJ (26 July 2010). The Scientific Basis of Urology. CRC Press. pp. 294–. ISBN   978-1-84184-749-8. Archived from the original on 14 April 2019. Retrieved 27 October 2017.
  20. 1 2 Melmed S, Polonsky KS, Larsen PR, Kronenberg MH (11 November 2015). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 709, 711, 765. ISBN   978-0-323-34157-8. Archived from the original on 14 April 2019. Retrieved 27 October 2017.
  21. 1 2 "Testosterone Undecanoate-Schering AG". Drugs in R&D. 5 (6): 368–369. 2004. doi:10.2165/00126839-200405060-00012. PMID   15563244. S2CID   43349541.
  22. 1 2 3 Meyer L (27 March 2019). "FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 7 September 2020. Retrieved 27 August 2020.
  23. ↑ Köhn FM, Schill WB (November 2003). "A new oral testosterone undecanoate formulation". World Journal of Urology. 21 (5): 311–315. doi:10.1007/s00345-003-0372-x. PMID   14579074. S2CID   23627346.
  24. ↑ Ahmad SW, Molfetto G, Montoya D, Camero A (August 2022). "Is Oral Testosterone the New Frontier of Testosterone Replacement Therapy?". Cureus. 14 (8): e27796. doi: 10.7759/cureus.27796 . PMC   9452423 . PMID   36106278.
  25. ↑ Ong GS, Somerville CP, Jones TW, Walsh JP (2012). "Anaphylaxis triggered by benzyl benzoate in a preparation of depot testosterone undecanoate". Case Reports in Medicine. 2012: 384054. doi: 10.1155/2012/384054 . PMC   3261473 . PMID   22272209. 384054.
  26. ↑ "Nebido Monograph – Information for Health Care Professionals". Bayer. 2016. Archived from the original on 19 October 2016. Retrieved 19 October 2016.
  27. 1 2 Payne AH, Hardy MP (28 October 2007). The Leydig Cell in Health and Disease. Springer Science & Business Media. pp. 423–. ISBN   978-1-59745-453-7. Archived from the original on 10 November 2020. Retrieved 6 October 2016.
  28. ↑ Täuber U, Schröder K, Düsterberg B, Matthes H (1986). "Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone". European Journal of Drug Metabolism and Pharmacokinetics. 11 (2): 145–149. doi:10.1007/BF03189840. PMID   3770015. S2CID   32305408.
  29. 1 2 Lemke TL, Williams DA (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1360–. ISBN   978-1-60913-345-0.
  30. ↑ Täuber U, Schröder K, Düsterberg B, Matthes H (April 1986). "Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone". European Journal of Drug Metabolism and Pharmacokinetics. 11 (2): 145–149. doi:10.1007/BF03189840. PMID   3770015.
  31. ↑ Behre HM, Nieschlag E, Nieschlag S (26 July 2012). "Testosterone preparations for clinical use in males". In Nieschlag E, Behre HM, Nieschlag S (eds.). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 309–335. doi:10.1017/CBO9781139003353.016. ISBN   978-1-107-01290-5.
  32. ↑ Hohl A (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 13–. ISBN   978-3-319-46086-4.
  33. ↑ Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS (March 2003). "Important effect of food on the bioavailability of oral testosterone undecanoate". Pharmacotherapy. 23 (3): 319–325. doi:10.1592/phco.23.3.319.32104. PMID   12627930. S2CID   24440953.
  34. ↑ Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB (April 2007). "The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps". Clinical Endocrinology. 66 (4): 579–585. doi:10.1111/j.1365-2265.2007.02781.x. PMC   1859980 . PMID   17371478.
  35. 1 2 Roth MY, Dudley RE, Hull L, Leung A, Christenson P, Wang C, et al. (December 2011). "Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride". International Journal of Andrology. 34 (6 Pt 1): 541–547. doi:10.1111/j.1365-2605.2010.01120.x. PMC   4269219 . PMID   20969601.
  36. ↑ Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, et al. (4 March 2012). "Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation". Journal of Andrology. 33 (2): 190–201. doi:10.2164/jandrol.111.013169. PMC   4168025 . PMID   21474786.
  37. 1 2 3 4 5 6 Behre HM, Wang C, Handelsman DJ, Nieschlag E (1 January 2001). "Pharmacology of testosterone preparations". Testosterone: 405–444. doi:10.1017/CBO9780511545221.015.
  38. 1 2 3 Lachance S, Dhingra O, Bernstein J, Gagnon S, Savard C, Pelletier N, et al. (November 2015). "Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials". Future Science OA. 1 (4): FSO55. doi:10.4155/fso.15.55. PMID   28031910.
  39. 1 2 3 4 5 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–642. ISBN   978-1-4757-2085-3. Archived from the original on 22 October 2020. Retrieved 6 October 2016.
  40. 1 2 3 4 5 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 1002–1004. ISBN   978-3-88763-075-1. Archived from the original on 25 January 2020. Retrieved 13 December 2017.
  41. ↑ Byrne MM, Nieschlag E (2017). "Androgens: Pharmacological Use and Abuse ☆". Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier. doi:10.1016/B978-0-12-809324-5.03356-3. ISBN   9780128093245.
  42. ↑ Tucker ME (7 March 2014). "FDA Approves Aveed Testosterone Jab, with Restrictions". Medscape . Archived from the original on 1 February 2017. Retrieved 13 December 2016.
  43. 1 2 3 Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. ISBN   978-94-011-4439-1. Archived from the original on 19 August 2020. Retrieved 6 October 2016.
  44. 1 2 3 "Testosterone". Drugs.com. Archived from the original on 13 November 2016. Retrieved 27 October 2017.
  45. ↑ "Testosterone undecanoate profile and most popular brands in USA". Downsizefitness.com. Archived from the original on 3 July 2022. Retrieved 6 September 2020.
  46. 1 2 3 4 Nieschlag E, Nieschlag S (2017). "The History of Testosterone and the Testes: From Antiquity to Modern Times". Testosterone. Springer. pp. 1–19. doi:10.1007/978-3-319-46086-4_1. ISBN   978-3-319-46084-0.
  47. ↑ Arnold AP, Pfaff DW, Etgen AM, Fahrbach SE, Rubin RT (10 June 2002). Hormones, Brain and Behavior, Five-Volume Set. Academic Press. pp. 20–. ISBN   978-0-12-532104-4. Archived from the original on 22 November 2020. Retrieved 27 October 2017.
  48. 1 2 "Drug Product Database". Health Canada. 18 March 2010. Archived from the original on 19 November 2016. Retrieved 13 November 2016.
  49. ↑ Karch SB (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN   978-1-4200-0346-8. Archived from the original on 14 April 2019. Retrieved 11 November 2017.
  50. ↑ Lilley LL, Snyder JS, Collins SR (5 August 2016). Pharmacology for Canadian Health Care Practice. Elsevier Health Sciences. p. 50. ISBN   978-1-77172-066-3. Archived from the original on 14 April 2019. Retrieved 11 November 2017.
  51. ↑ "Clarus Therapeutics Receives U.S. FDA Approval of Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men". Clarustherapeutics.com. Archived from the original on 19 February 2020. Retrieved 14 March 2022.
  52. 1 2 "Drug Approval Package: Kyzatrex Capsules". accessdata.fda.gov. 21 December 2022. Retrieved 18 May 2024.
  53. ↑ "Kyzatrex (testosterone undecanoate) FDA Approval History". Drugs.com. Archived from the original on 6 April 2023. Retrieved 6 April 2023.
  54. ↑ "Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis". Clinicaltrials.gov. 25 April 2017. Archived from the original on 9 April 2021. Retrieved 14 March 2022.
  55. ↑ "Lipocine Inc. - Clinical Trials". Lipocine.com. Archived from the original on 24 May 2019. Retrieved 14 March 2022.
  56. ↑ Wang YJ, Zhan JK, Huang W, Wang Y, Liu Y, Wang S, et al. (2013). "Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone". International Journal of Endocrinology. 2013: 570413. doi: 10.1155/2013/570413 . PMC   3603196 . PMID   23533404.
  57. ↑ Snyder P (December 2022). "Testosterone treatment of late-onset hypogonadism - benefits and risks". Rev Endocr Metab Disord. 23 (6): 1151–1157. doi:10.1007/s11154-022-09712-1. PMID   35266057.
  58. ↑ Saad F, Doros G, Haider KS, Haider A (June 2020). "Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study". International Journal of Obesity. 44 (6): 1264–1278. doi:10.1038/s41366-019-0517-7. PMC   7260126 . PMID   32060355. S2CID   211102413.
  59. ↑ Aversa A, Bruzziches R, Francomano D, Greco EA, Fornari R, Di Luigi L, et al. (June 2012). "Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study". The Aging Male. 15 (2): 96–102. doi: 10.3109/13685538.2011.631230 . PMID   22439807. S2CID   6594250.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.